Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to I^TM), announced  that it has entered into a strategic collaboration with Invetx, Inc. ("Invetx"), a Boston-based animal biotechnology company, to develop next-generation animal health biotherapeutics using Nona's HCAb Harbour Mice^® platform.

Nona Biosciences' proprietary Harbour Mice^® platform generates monoclonal antibodies in both conventional (H2L2) and heavy chain-only (HCAb) formats. The HCAb Harbour Mice^® platform is revolutionizing antibody development by producing unique heavy chain-only antibodies that are approximately half the size of conventional IgGs, offering significant advantages for next-generation antibody therapies. The technology is clinically validated, globally patent protected, and worldwide endorsed and recognized.

Jingsong Wang, MD, PhD, Chairman of Nona Biosciences, commented: "This collaboration marks an important milestone as we expand our business into the animal health sector for the first time, demonstrating the flexibility and broad application of our Harbour Mice^® technology. By leveraging our innovative platform, we aim to empower Invetx in advancing novel therapeutics that address critical needs in animal health."

Juergen Horn, DVM, PhD, President of Invetx, added, "We are excited to partner with Nona as we continue our work to create novel, protein-based animal health therapeutics. By leveraging Nona's HCAbs, we are accelerating the development of our clinical program to demonstrate the safety and efficacy of our differentiated technology platforms."